Presentation and Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand via Elongated Plant Viral Nanoparticle Enhances Antitumor Efficacy
Source abstract
Abstract
Potato virus X (PVX) is a flexuous plant virus-based nanotechnology with promise in cancer therapy. As a high aspect ratio biologic (13 × 515 nm), PVX has excellent spatial control in structures and functions, offering high-precision nanoengineering for multivalent display of functional moieties. Herein, we demonstrate the preparation of the PVX-based nanocarrier for delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a promising protein drug that induces apoptosis in cancer cells but not healthy cells. TRAIL bound to PVX by coordination bonds between nickel-coordinated nitrilotriacetic acid on PVX and His-tag on the protein could mimic the bioactive "membrane-bound" state in native TRAIL, resulting in an elongated nanoparticle displaying up 490 therapeutic protein molecules. Our data show that PVX-delivered TRAIL activates caspase-mediated apoptosis more efficiently compared to soluble TRAIL; also in vivo the therapeutic nanoparticle outperforms in delaying tumor growth in an athymic nude mouse model bearing human triple-negative breast cancer xenografts. This proof-of-concept work highlights the potential of filamentous plant virus nanotechnologies, particularly for targeting protein drug delivery for cancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Cell death mechanisms and regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, United States
Department of Molecular Biology, RWTH-Aachen University, Aachen 52064, Germany
Department of NanoEngineering, Moores Cancer Center, Department of Radiology, Department of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States
Funding
American Cancer Society
References (54)
Show source-provided references
1. 10.1186/1756-9966-30-8710.1186/1756-9966-30-87 ↗
2. 10.1038/8341610.1038/83416 ↗
3. 10.1016/j.ceb.2010.08.00110.1016/j.ceb.2010.08.001 ↗
4. 10.1038/nrc246510.1038/nrc2465 ↗
5. 10.1038/sj.cdd.440118710.1038/sj.cdd.4401187 ↗
6. 10.1038/cddis.2010.4510.1038/cddis.2010.45 ↗
7. 10.1016/j.molmed.2013.08.00710.1016/j.molmed.2013.08.007 ↗
8. 10.1200/JCO.2009.25.199110.1200/JCO.2009.25.1991 ↗
9. 10.1158/1535-7163.MCT-12-035810.1158/1535-7163.MCT-12-0358 ↗
10. 10.1172/JCI8042010.1172/JCI80420 ↗
11. 10.1002/anie.20140303610.1002/anie.201403036 ↗
12. 10.1039/C7NR01469D10.1039/C7NR01469D ↗
13. 10.1021/acsnano.7b0587610.1021/acsnano.7b05876 ↗
14. 10.1016/j.leukres.2015.03.01910.1016/j.leukres.2015.03.019 ↗
15. 10.1016/j.jconrel.2012.07.02110.1016/j.jconrel.2012.07.021 ↗
16. 10.1007/s11095-015-1814-z10.1007/s11095-015-1814-z ↗
17. 10.1038/nmat343010.1038/nmat3430 ↗
18. 10.1021/bc400517j10.1021/bc400517j ↗
19. 10.1038/nbt.333010.1038/nbt.3330 ↗
20. 10.1021/acs.chemrev.7b0019410.1021/acs.chemrev.7b00194 ↗
21. 10.1002/anie.20120914510.1002/anie.201209145 ↗
22. 10.1016/S1369-7021(11)70161-410.1016/S1369-7021(11)70161-4 ↗
23. 10.1016/j.ijpharm.2015.03.03210.1016/j.ijpharm.2015.03.032 ↗
24. 10.1021/nl503565t10.1021/nl503565t ↗
25. 10.1021/acsnano.5b0736010.1021/acsnano.5b07360 ↗
26. 10.1021/acs.molpharmaceut.7b0046610.1021/acs.molpharmaceut.7b00466 ↗
27. 10.1039/C6NR09099K10.1039/C6NR09099K ↗
28. 10.1007/978-1-62703-751-8_110.1007/978-1-62703-751-8_1 ↗
29. 10.1016/j.colsurfb.2015.03.03910.1016/j.colsurfb.2015.03.039 ↗
30. 10.1016/j.jsb.2017.06.00610.1016/j.jsb.2017.06.006 ↗
31. 10.1016/j.biomaterials.2016.12.03010.1016/j.biomaterials.2016.12.030 ↗
32. 10.1021/acs.nanolett.7b0010710.1021/acs.nanolett.7b00107 ↗
33. 10.1021/bc500545z10.1021/bc500545z ↗
34. 10.1039/c3bm60277j10.1039/c3bm60277j ↗
35. 10.1021/nl903575310.1021/nl9035753 ↗
36. 10.1039/C7TB03106H10.1039/C7TB03106H ↗
37. 10.1021/acs.molpharmaceut.7b0055910.1021/acs.molpharmaceut.7b00559 ↗
38. 10.1002/anie.20130218110.1002/anie.201302181 ↗
39. 10.1038/8639710.1038/86397 ↗
40. 10.1016/j.canlet.2016.10.00510.1016/j.canlet.2016.10.005 ↗
41. 10.1016/S0065-230X(09)03003-610.1016/S0065-230X(09)03003-6 ↗
42. 10.1007/s10549-008-9924-510.1007/s10549-008-9924-5 ↗
43. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
44. 10.1021/nn404501g10.1021/nn404501g ↗
45. 10.1016/S1040-8428(01)00214-110.1016/S1040-8428(01)00214-1 ↗
46. 10.1158/1078-0432.CCR-09-244310.1158/1078-0432.CCR-09-2443 ↗
47. 10.1038/ncomms1417910.1038/ncomms14179 ↗
48. 10.1021/mp300258c10.1021/mp300258c ↗
49. 10.1073/pnas.131631211110.1073/pnas.1316312111 ↗
50. 10.1016/j.biomaterials.2018.07.00910.1016/j.biomaterials.2018.07.009 ↗
51. 10.1073/pnas.141896211210.1073/pnas.1418962112 ↗
52. 10.1038/cdd.2015.17410.1038/cdd.2015.174 ↗
53. 10.1073/pnas.070765410510.1073/pnas.0707654105 ↗
54. 10.1016/j.actbio.2015.03.00110.1016/j.actbio.2015.03.001 ↗